Patient demand for testosterone therapy has surged, driven by social media influencers, anti-aging clinics, and genuine frustration with symptoms that disrupt quality of life. The marketing promises vitality, mental clarity, better sleep, and renewed desire.
But here’s what most people don’t know: there is no FDA-approved testosterone product for women in the United States. None. We’re navigating off-label prescribing, compounded formulations, and a significant gap between what patients expect and what the evidence actually supports.
The clinical reality is more complex than these promises suggest.
The Evidence Is Narrow—and That Matters
Testosterone therapy for women has one well-supported indication: postmenopausal hypoactive sexual desire disorder.
The 2019 Global Consensus Position Statement and the International Society for the Study of Women’s Sexual Health (ISSWSH) clinical practice guideline both support testosterone use in this specific context. Meta-analyses show a statistically significant effect on sexual desire and the number of satisfying sexual events.
But the effect is modest. We’re talking about meaningful improvement for some women, not a universal transformation.
What testosterone is not evidence-based for:
- Energy and fatigue
- Mood disorders or depression
- Cognitive function or brain fog
- Bone density
- Body composition or weight loss
The “vitality” claims you see in anti-aging marketing consistently outrun the data. I tell my patients this upfront. If you’re coming to me for testosterone to fix your energy or help you lose weight, I need to redirect that conversation.
The “Low Testosterone Equals Low Libido” Myth
This is the part that surprises people.
There is no consistent correlation between serum testosterone levels and sexual desire in women. You can have low testosterone and a healthy libido. You can have normal testosterone and no desire at all.
Testosterone levels fluctuate throughout the day and across the menstrual cycle. The reference ranges for women are broad and poorly standardized. Most commercial labs aren’t even validated for measuring the low concentrations found in women.
So when a patient asks me to “check her levels,” I explain that the number on the lab report won’t tell us what we need to know. Testosterone therapy is a therapeutic trial for a specific symptom, not a laboratory deficiency to be corrected.
I don’t treat a number. I treat a person.
How I Prescribe Testosterone Responsibly
Because there’s no FDA-approved testosterone product for women, I have two options: use approved male formulations off-label at much lower doses, or prescribe compounded products.
I prefer using physiologic dosing with commercially available male formulations when possible. This gives me more consistency and quality control. Compounded products can vary in potency and purity, which makes monitoring harder.
Here’s my approach:
Dosing: I aim for physiologic replacement, keeping women in the upper end of the normal female range. This usually means 1-2 mg of testosterone per day, delivered via transdermal cream or gel.
Monitoring: I check testosterone levels 4-6 weeks after starting therapy, then periodically to make sure we’re not overshooting into supraphysiologic territory. I also monitor for androgenic side effects.
Counseling: I discuss the potential for acne, hair growth, voice changes, and clitoral enlargement. These effects are dose-dependent and usually reversible if we catch them early and adjust.
I also tell patients what we don’t know: long-term cardiovascular safety and breast cancer risk. The data isn’t there yet. We have reassuring short-term studies, but no long-term randomized controlled trials.
This is informed consent. I want my patients to understand the limits of our knowledge.
What We Still Don’t Know
The absence of long-term safety data is the biggest gap in this conversation.
We don’t have definitive answers on cardiovascular outcomes. We don’t have clear data on breast cancer risk. The studies we do have are short-term, often industry-sponsored, and conducted in carefully selected populations.
A January 2026 systematic review in Sexual Medicine Reviews highlighted these knowledge gaps. The FDA has issued new guidance on a development pathway for female testosterone products, which is encouraging. But we’re still years away from having an approved product with robust long-term safety data.
In the meantime, I practice cautiously. I prescribe testosterone when the indication is clear, the patient is informed, and we have a plan for monitoring and follow-up.
How I Respond to “Vitality” Marketing
The anti-aging industry has latched onto testosterone as a fountain of youth for women.
You see ads promising better sleep, sharper thinking, effortless weight loss, and boundless energy. The messaging is seductive, especially for women in midlife who feel dismissed by conventional medicine.
But these claims are not supported by evidence.
When a patient comes to me with expectations shaped by this marketing, I don’t dismiss her concerns. I listen. I validate her symptoms. Then I walk her through what we actually know and what treatment options are evidence-based.
Sometimes that includes testosterone. Often it doesn’t.
I might address her sleep with cognitive behavioral therapy for insomnia. I might treat her mood with counseling or an antidepressant. I might optimize her thyroid function or adjust her menopausal hormone therapy.
The point is this: testosterone is not a cure-all, and I won’t prescribe it as one.
The Path Forward
I’m hopeful that we’ll have better data and better products in the coming years. The ISSWSH guidelines provide a solid framework for clinicians who want to prescribe testosterone responsibly. The FDA’s new development pathway signals regulatory recognition of a real clinical need.
But until we have long-term safety data and an approved product, I’m going to keep practicing with caution and transparency.
I’ll prescribe testosterone for postmenopausal women with hypoactive sexual desire disorder when the diagnosis is clear and the patient understands the risks and benefits. I’ll monitor carefully. I’ll adjust when needed. And I’ll be honest about what we don’t know.
That’s the standard of care I hold myself to.
If you’re considering testosterone therapy, find a clinician who will have this conversation with you. Ask about the evidence. Ask about monitoring. Ask about long-term safety.
You deserve informed consent, not marketing hype.
George Delaney MD
Dr. George Delaney is the Owner and Medical Director of Delaney MD Aesthetics and Anti-Aging at Elysium Medical Arts Center in Edmonds, Washington, just north of Seattle.
Dr. Delaney’s educational and professional journey:
Obtained his Bachelor of Science degree from the University of Washington. Received his medical degree at the Medical College of Wisconsin in Milwaukee, in 1995. Completed his internship and residency training in Family Medicine residency at Oregon Health and Science University in Portland, Oregon. After residency, he worked in primary care for the underserved, underinsured, and Hispanic community in a health care center, south of Salt Lake City, Utah,
In the healthcare center, he worked with individuals that had and needed treatment for:
– Hypertension
– Diabetes
– Elevated lipids
– Obesity
– Wellness care for infants, children, adolescents, and pregnant women
– Delivery of 1,500 infants including cesarean-section assists.
– Oversaw & managed the colposcopy clinic
Dr. Delaney is highly respected in the community and by his peers for his advanced training and expertise.
– Received Two Fellowships – an Aesthetics Fellowship and a Functional Medicine Fellowship
– Board certification as a member of the American Board of Anti-Aging… Read more
